FDA-cleared profile

TumorSight Viz

SimBioSys, Inc. · MRI · FDA-cleared (510(k))

Authorized purpose: Visualize and analyze DCE breast MRI studies for patients with biopsy-proven early-stage or locally advanced breast cancer, including processing, measurements, and configurable finding visualization; results are not a sole basis for patient management.

Clinical role
Breast MRI visualization, post-processing, segmentation, and measurement aid for clinician review and management or planning decisions.
Images and patients
MRI · Breast, including biopsy-proven breast tumors/findings.
Key limitation
Keep in mind: Patient management decisions must not be made solely from the results. The labeled context is contrast-enhanced breast MRI for biopsy-proven early-stage or locally advanced breast cancer; clinician review is required before use in planning.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Visualize and analyze DCE breast MRI studies for patients with biopsy-proven early-stage or locally advanced breast cancer, including processing, measurements, and configurable finding visualization; results are not a sole basis for patient management.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Breast, including biopsy-proven breast tumors/findings. Input: DICOM dynamic contrast-enhanced breast MRI studies acquired during contrast administration from patients with biopsy-proven early-stage or locally advanced breast cancer.
  • Who uses it?Intended users: Skilled or qualified physicians interpreting and reviewing breast MRI analysis.
  • What does the software produce?Output: Standard image views, MIPs, reformats, registrations, subtraction series, kinetic curves, parametric maps, segmentation and 3D volume renderings, automated linear and volume measurements, finding visualization, and DICOM import/retrieval/storage through the web application.
  • What is its most important limitation?Key limitation: Patient management decisions must not be made solely from the results. The labeled context is contrast-enhanced breast MRI for biopsy-proven early-stage or locally advanced breast cancer; clinician review is required before use in planning.

Clinical takeaway. Clinical role: Visualize and analyze DCE breast MRI studies for patients with biopsy-proven early-stage or locally advanced breast cancer, including processing, measurements, and configurable finding visualization; results are not a sole basis for patient management.

Evidence takeaway. Evidence from the reviewed source record: FDA K243189 describes training/tuning data from 833 patients (916 samples) and an independent validation set from 216 patients (217 samples) at more than seven U.S. clinical sites; all patients had pathologically confirmed invasive early-stage or locally advanced breast cancer. Three board-certified radiologists established validation ground truth. Validation measurement mean absolute errors included tumor volume 5.22 +/- 15.58 cc, longest dimension 1.60 +/- 1.93 cm, tumor-to-nipple distance 1.20 +/- 1.37 cm, tumor-to-skin distance 0.63 +/- 0.61 cm, and tumor-to-chest distance 0.91 +/- 1.14 cm. Tumor segmentation volumetric Dice was 0.75 +/- 0.24 and surface Dice 0.88 +/- 0.24. A separate 197-case predicate comparison was also reported.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Visualize and analyze DCE breast MRI studies for patients with biopsy-proven early-stage or locally advanced breast cancer, including processing, measurements, and configurable finding visualization; results are not a sole basis for patient management.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Breast MRI visualization, post-processing, segmentation, and measurement aid for clinician review and management or planning decisions.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
DICOM dynamic contrast-enhanced breast MRI studies acquired during contrast administration from patients with biopsy-proven early-stage or locally advanced breast cancer.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Standard image views, MIPs, reformats, registrations, subtraction series, kinetic curves, parametric maps, segmentation and 3D volume renderings, automated linear and volume measurements, finding visualization, and DICOM import/retrieval/storage through the web application.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Breast MRI oncology and post-processing workflow for biopsy-proven early-stage or locally advanced breast cancer; facility type is not specified.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Skilled or qualified physicians interpreting and reviewing breast MRI analysis.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Patient management decisions must not be made solely from the results. The labeled context is contrast-enhanced breast MRI for biopsy-proven early-stage or locally advanced breast cancer; clinician review is required before use in planning.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA K243189 describes training/tuning data from 833 patients (916 samples) and an independent validation set from 216 patients (217 samples) at more than seven U.S. clinical sites; all patients had pathologically confirmed invasive early-stage or locally advanced breast cancer. Three board-certified radiologists established validation ground truth. Validation measurement mean absolute errors included tumor volume 5.22 +/- 15.58 cc, longest dimension 1.60 +/- 1.93 cm, tumor-to-nipple distance 1.20 +/- 1.37 cm, tumor-to-skin distance 0.63 +/- 0.61 cm, and tumor-to-chest distance 0.91 +/- 1.14 cm. Tumor segmentation volumetric Dice was 0.75 +/- 0.24 and surface Dice 0.88 +/- 0.24. A separate 197-case predicate comparison was also reported.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA K243189 describes training/tuning data from 833 patients (916 samples) and an independent validation set from 216 patients (217 samples) at more than seven U.S. clinical sites; all patients had pathologically confirmed invasive early-stage or locally advanced breast cancer. Three board-certified radiologists established validation ground truth. Validation measurement mean absolute errors included tumor volume 5.22 +/- 15.58 cc, longest dimension 1.60 +/- 1.93 cm, tumor-to-nipple distance 1.20 +/- 1.37 cm, tumor-to-skin distance 0.63 +/- 0.61 cm, and tumor-to-chest distance 0.91 +/- 1.14 cm. Tumor segmentation volumetric Dice was 0.75 +/- 0.24 and surface Dice 0.88 +/- 0.24. A separate 197-case predicate comparison was also reported.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

TumorSight Viz regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K243189
  • Samplen=833
  • Sites9
  • IndependenceIndependence not established

K243189

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K243189. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM dynamic contrast-enhanced breast MRI studies acquired during contrast administration from patients with biopsy-proven early-stage or locally advanced breast cancer.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K243189: TumorSight Viz

  2. Routing

    Source context, not route validation: Cloud-hosted software accessed through the TumorSight web application on an internet-connected computer; DICOM import, retrieval, study storage, and automated image import are described. A specific PACS/RIS/EHR interface is not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K243189: TumorSight Viz

  3. AI processing

    Source context, not route validation: The exact FDA package describes proprietary software hosted on a cloud-based platform and accessed on an off-the-shelf computer, with results processed and displayed on the TumorSight web application. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "The TumorSight system consists of proprietary software developed by SimBioSys, Inc. hosted on a cloud-based platform and accessed on an off-the-shelf computer." … "TumorSight processes and displays the results on the TumorSight web application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K243189: TumorSight Viz

  4. Returned objects

    Source context, not route validation: Standard image views, MIPs, reformats, registrations, subtraction series, kinetic curves, parametric maps, segmentation and 3D volume renderings, automated linear and volume measurements, finding visualization, and DICOM import/retrieval/storage through the web application.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K243189: TumorSight Viz

  5. Viewer/worklist/report

    Unresolved route: Standard image views, MIPs, reformats, registrations, subtraction series, kinetic curves, parametric maps, segmentation and 3D volume renderings, automated linear and volume measurements, finding visualization, and DICOM import/retrieval/storage through the web application.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K243189: TumorSight Viz

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes proprietary software hosted on a cloud-based platform and accessed on an off-the-shelf computer, with results processed and displayed on the TumorSight web application. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The TumorSight system consists of proprietary software developed by SimBioSys, Inc. hosted on a cloud-based platform and accessed on an off-the-shelf computer." … "TumorSight processes and displays the results on the TumorSight web application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
Cloud-hosted software accessed through the TumorSight web application on an internet-connected computer; DICOM import, retrieval, study storage, and automated image import are described. A specific PACS/RIS/EHR interface is not established.
  • Exact FDA submission
  • Checked 2026-09-08

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for TumorSight Viz; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243189
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Breast, including biopsy-proven breast tumors/findings.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-10-25
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
21Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K243189 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-08 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K243189: TumorSight Viz

    U.S. Food and Drug Administration - Published 2024-10-25 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. TumorSight Viz model card (K243189)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: intendedUsers, output, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K243189

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

Research history

  1. K243189 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251766

TumorSight Viz

SimBioSys, Inc.

Authorized purpose: TumorSight Viz processes dynamic contrast-enhanced breast MRI for patients with biopsy-proven early-stage or locally advanced breast cancer, providing registration, subtraction, segmentation, 3D renderings, measurements, kinetic curves, parametric maps, MIPs, and reformats for physician visualization and analysis; results are not the sole basis for patient management.

Modality
MRI
Anatomy
Breast
Decision
2025-07-08
FDA-cleared K231130

TumorSight Viz

SimBioSys, Inc.

Authorized purpose: TumorSight Viz analyzes dynamic contrast-enhanced breast MRI for visualization and analysis of biopsy-proven early-stage or locally advanced breast cancer, including registration, subtraction, measurements, and three-dimensional views to support physician review.

Modality
MRI
Anatomy
Breast; early-stage or locally advanced breast cancer
Decision
2023-12-26
FDA-cleared K253413

LiverMultiScan (v6.0)

Perspectum, Ltd.

Authorized purpose: LiverMultiScan v6.0 is MR diagnostic software for non-invasive liver-health assessment that generates, displays, and supports review of MR data and quantitative cT1, PDFF, and LIC metrics or composite images for trained healthcare-professional interpretation.

Modality
MRI
Anatomy
Liver
Decision
2026-03-09
FDA-cleared K252922

Neosoma Brain Mets

Neosoma, Inc.

Authorized purpose: Neosoma Brain Mets semi-automatically segments and contours previously diagnosed brain metastases on T1 post-contrast brain MRI to support radiation-oncology treatment planning.

Modality
MRI
Anatomy
Brain; previously diagnosed brain metastases
Decision
2025-12-17

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history